

FAX RECEIVED

FAX

AUG 04 2003



GROUP 1600

**To** Group 1614

**Company** USPTO

**Fax** 703-872-9306

**From** Allyson K. Jacobs

**Tel** 919-483-9105 **Fax** 919-483-7988

**E-mail** [akj27836@glaxowellcome.com](mailto:akj27836@glaxowellcome.com)

**Date** 01-Aug-2003 **Pages including cover** 5

**Subject** Serial No.: 10/018,640

**Filing Date:** 3/20/02

OFFICIAL

Glaxo Wellcome Inc.

PO Box 13398

Five Moore Drive

Research Triangle Park

North Carolina 27709

Tel: 919 483 2100

[www.gsk.com](http://www.gsk.com)

Attached:

Amendment Transmittal  
Response to Restriction  
Certificate of Transmission

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

PTO/SB/97 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the  
United States Patent and Trademark Office

on 8/1/03  
Date

Allyson K. Jacobs

Signature

Allyson K. Jacobs  
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify  
each submitted paper.

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-8199 and select option 2

AUG. 1. 2003 12:24PM

GLAXO WELLCOME

NO. 9886 P. 2

## AMENDMENT TRANSMITTAL LETTER (Large Entity)

Applicant(s): Burbidge et al.

Docket No.  
PG3733USWSerial No.  
10/018,640Filing Date  
3/20/02Examiner  
Dwayne C. JonesGroup Art Unit  
1614

Invention: NEW USES FOR POTASSIUM CHANNEL OPENERS

TO THE COMMISSIONER FOR PATENTS:

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

## CLAIMS AS AMENDED

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	8	20 =	0	x \$18.00	\$0.00
INDEP. CLAIMS	8	8 =	0	x \$84.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00

No additional fee is required for amendment.

Please charge Deposit Account No. in the amount of

A check in the amount of to cover the filing fee is enclosed.

The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 07-1392

Any additional filing fees required under 37 C.F.R. 1.16.

Any patent application processing fees under 37 CFR 1.17.

Bonnie L. Deppenbrock  
Signature

Dated: 1 August 2003

Bonnie L. Deppenbrock, Reg. No. 28,209  
Attorney for Applicants  
GlaxoSmithKline  
Five Moore Drive, PO Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-1577  
Facsimile: (919) 483-7988

I certify that this document and fee is being deposited on with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

CC:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Burbidge et al

Serial No.: 10/018,640

Examiner: Dwayne C. Jones

Filing Date: March 20, 2002

Art Unit: 1614

For: NEW USES FOR POTASSIUM CHANNEL OPENERS

Commissioner for Patents  
Washington D.C. 20231

RESPONSE TO RESTRICTION

Sir:

This paper is submitted in response to the Office Action mailed July 1, 2003, for which a 1-month shortened statutory period to respond was set. Accordingly, this paper is timely filed on or before August 1, 2003. Early examination of the application on the merits is earnestly solicited.

Remarks begin on page 2 of this paper.